OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Deek on Vismodegib Plus Radiation in Locally Advanced Unresectable Basal Cell Carcinoma

November 29th 2024

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Dr Schmid on Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage TNBC

November 29th 2024

Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.

Dr Sonpavde on the Implications of the NIAGARA Trial Regimen in Bladder Cancer

November 27th 2024

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

Dr Rimm on the Effect of Inaccurate HER2 IHC Testing for Patients With Breast Cancer

November 27th 2024

David Rimm, MD, PhD, discusses the effect of inaccurate HER2 immunohistochemistry testing on the subclassification of patients with breast cancer.

Dr Kamath on the Rise in Incidence of Pancreatic Cancer

November 27th 2024

Suneel Kamath, MD, discusses the rising incidence of pancreatic cancer during Pancreatic Cancer Awareness Month.

Dr Moore on Key 2024 Updates in FRα+ Ovarian Cancer Management

November 27th 2024

Dr Kumar on the 2024/2025 NCCN Treatment Updates in Myeloma

November 27th 2024

Shaji Kumar, MD, discusses 2024 updates made to the NCCN guidelines for multiple myeloma treatment, as well as the first 2025 updates.

Dr Sharma on the Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

November 27th 2024

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Dr Tawagi on the Growing Role of Precision Medicine in Prostate Cancer

November 27th 2024

Karine Tawagi, MD, discusses the use of targeted therapies in the management of metastatic prostate cancer.

Dr Stearns on the Efficacy of Avelumab in TNBC

November 27th 2024

Vered Stearns, MD, discusses the efficacy of avelumab as adjuvant therapy in patients with early triple-negative breast cancer.

Dr Martin on the Role of BTK Inhibitors in the Management of MCL

November 27th 2024

Peter Martin, MD, discusses the role of BTK inhibitors in the treatment of mantle cell lymphoma.

Dr Watts on the Potential Advantages of INCB057643 in Advanced Myelofibrosis

November 27th 2024

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Dr Moore on Ongoing ADC Development in Ovarian Cancer

November 27th 2024

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates under investigation in ovarian cancer.

Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC

November 26th 2024

Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.

Dr Kumthekar on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease

November 25th 2024

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

November 25th 2024

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

November 24th 2024

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma

November 23rd 2024

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer

November 23rd 2024

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

November 23rd 2024

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.